<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01834963</url>
  </required_header>
  <id_info>
    <org_study_id>KHBO1207</org_study_id>
    <secondary_id>UMIN000010425</secondary_id>
    <nct_id>NCT01834963</nct_id>
  </id_info>
  <brief_title>P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.</brief_title>
  <official_title>Randomised Phase II Study of Postoperative Hepatic Arterial Infusion Chemotherapy (Interferon/Fluorouracil Versus Low-dose Cisplatin/Fluorouracil) for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Hepatobiliary Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansai Hepatobiliary Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of postoperative hepatic arterial infusion chemotherapy,&#xD;
      interferon/fluorouracil versus low-dose cisplatin/fluorouracil, in patients with&#xD;
      hepatocellular carcinoma with portal vein tumor thrombus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No standard treatment has been established for highly advanced hepatocellular carcinoma (HCC)&#xD;
      invading the major branches of the portal vein except for sorafenib. Some reports suggested&#xD;
      that hepatic arterial infusion chemotherapy improved survival of these patients. Other&#xD;
      reports indicated surgical intervention improved that survival. However, there is no standard&#xD;
      adjuvant therapy after liver resection for the patients with HCC with portal vein tumor&#xD;
      thrombus in the main or first branch of the portal vein. Our preliminary results showed that&#xD;
      combined interferon-alpha and intra-arterial 5-fluorouracil (5-FU) as a postoperative therapy&#xD;
      prolonged disease-free and overall survival after liver resection. Hepatic arterial infusion&#xD;
      chemotherapy using low-dose 5-FU and cisplatin is also promising regimen for advanced HCC.&#xD;
&#xD;
      Herein, the investigators planed the study to evaluate efficacy (two year survival as primary&#xD;
      outcome, and overall-survival as secondary outcome) and safety ( as secondary outcome) in&#xD;
      hepatic arterial infusion chemotherapy with continuous infusion of 5-fluorouracil and&#xD;
      systemic administration of interferon-alpha or low-dose 5-FU and cisplatin, and to compare&#xD;
      the efficacy as randomized control trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year overall survival rate</measure>
    <time_frame>Two years</time_frame>
    <description>Duration: From randomization to evidenced death.&#xD;
Rate: Number of patients with evidenced death / number of total patients.&#xD;
2 year survival rate: survival rate at two-year from the randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>two years</time_frame>
    <description>Progression free survival time from randomization to tumor progression based on RECIST or recurrence after curative surgery was calculated by Kaplan Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>two years</time_frame>
    <description>Overall survival time from randomization to evidence death was calculated by Kaplan Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>At the end of hepatic arterial infusion chemotherapy (6 months)</time_frame>
    <description>The incidence of adverse events evaluated by CTCAE Ver4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Interferon Alfa、Fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks&#xD;
Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin、Fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks&#xD;
Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa、Fluorouracil</intervention_name>
    <description>Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha&#xD;
Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks&#xD;
Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks</description>
    <arm_group_label>Interferon Alfa、Fluorouracil</arm_group_label>
    <other_name>Interferon Alfa ; IFN、</other_name>
    <other_name>Fluorouracil ; 5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin、Fluorouracil</intervention_name>
    <description>Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)&#xD;
Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks&#xD;
Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks</description>
    <arm_group_label>Cisplatin、Fluorouracil</arm_group_label>
    <other_name>Cisplatin ； Cispulan</other_name>
    <other_name>Fluorouracil ; 5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. hepatocellular carcinoma with histological or evidence or typical findings by CT or&#xD;
             MRI.&#xD;
&#xD;
          2. surgically resectable tumors with tumor thrombus in first branch or main trunk of&#xD;
             portal vein.&#xD;
&#xD;
          3. 20 years old or more.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance status of 0 or 1.&#xD;
&#xD;
          5. Life expectancy of at least 6 months at the pre-treatment evaluation.&#xD;
&#xD;
          6. Child-Pugh class A or B.&#xD;
&#xD;
          7. Adequate bone marrow, liver and renal function, as assessed by the following&#xD;
             laboratory requirements.&#xD;
&#xD;
        white blood cell count &gt;= 2000/microliter, Neutrophil &gt;= 1000/microliter, Hemoglobin &gt;= 9.0&#xD;
        g/dL, Platelet count &gt;= 75000/microliter, Total Bilirubin &lt;= 1.5mg/dl, aspartate&#xD;
        aminotransferase(AST) /alanine aminotransferase(ALT) &lt;= 150 IU/L, Serum creatinine &lt;=&#xD;
        1.2mg/dL, Creatinine clearance &gt;= 60 ml/min&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosed combined hepatocellular and cholangiocellular carcinoma.&#xD;
&#xD;
          2. Extrahepatic tumor spread which affects patient's prognosis.&#xD;
&#xD;
          3. Hepatic encephalopathy&#xD;
&#xD;
          4. Active infections except for hepatitis B virus(HBV) and hepatitis C virus(HCV).&#xD;
&#xD;
          5. Sever complications (interstitial pneumonia, heart failure, renal failure, liver&#xD;
             failure, ileus, incontrollable diabetes mellitus, and so on)&#xD;
&#xD;
          6. Active double cancer&#xD;
&#xD;
          7. Pregnancy 8-10) Medication or treatment that may affect to the absorption of drug or&#xD;
             pharmacokinetics.&#xD;
&#xD;
        11) others, in the investigator's judgment.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Nagano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University, Graduate School of Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Wada</last_name>
      <phone>+81-6-6879-3251</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

